Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial-Reference-Cited by-同舟云学术

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

Published:2016-05 Issue:5 Volume:17 Page:622-631
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Younes Anas,Berdeja Jesus G,Patel Manish R,Flinn Ian,Gerecitano John F,Neelapu Sattva S,Kelly Kevin R,Copeland Amanda R,Akins Amy,Clancy Myles S,Gong Lucy,Wang Jing,Ma Anna,Viner Jaye L,Oki Yasuhiro

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11;Ferlay,2013

2. New and emerging HDAC inhibitors for cancer treatment;West;J Clin Invest,2014

3. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics;Akinleye;J Hematol Oncol,2013

4. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling;Qian;Clin Cancer Res,2012

5. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM-and MCL-1–dependent mechanisms in vitro and in vivo;Rahmani;Clin Cancer Res,2014

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classical Monocytes Shuttling for Precise Delivery of Nanotherapeutics to Glioblastoma;Advanced Healthcare Materials;2024-08-30

2. Lysine lactylation in the regulation of tumor biology;Trends in Endocrinology & Metabolism;2024-08

3. A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets;Pathology - Research and Practice;2024-08

4. Rethinking therapeutic strategies of dual‐target drugs: An update on pharmacological small‐molecule compounds in cancer;Medicinal Research Reviews;2024-05-20

5. Epigenetic regulation in cancer therapy: From mechanisms to clinical advances;MedComm – Oncology;2024-01-04